Recently, LRP1B association with tumor mutational burden and immunotherapy efficacy has been confirmed in lung and hepatocellular carcinomas, revealing the gene mutational status as a potential biomarker for immune check-point inhibitors (ICI) treatment response, through mast cells activation and infiltration in tumor tissues [23, 24]. Here, LRP1B is linked to hepatocellular carcinoma.